Effects of rosiglitazone on radioiodine negative and progressive differentiated thyroid carcinoma as assessed by 124I PET/CT imaging

Clinical Nuclear Medicine

Volumn 37, Issue 3, 2012, Pages

  Rosenbaum Krumme, Sandra Julia ^a   Freudenberg, Lutz Stefan ^a   Jentzen, Walter ^a   Bockisch, Andreas ^a   Nagarajah, James ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

124I PET CT; Redifferentiation; Rosiglitazone; Thyroid cancer

Indexed keywords

IOBITRIDOL; IODINE 124; RECOMBINANT THYROTROPIN; ROSIGLITAZONE; SODIUM I 124; THYROGLOBULIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE ATROPHY; CANCER PATIENT; CANCER SIZE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIFFERENTIATED THYROID CANCER; DOSIMETRY; DRUG ABSORPTION; DRUG HALF LIFE; DRUG WITHDRAWAL; FEMALE; HEART FAILURE; HUMAN; LESIONAL ABSORBED DOSE; MALE; OFF LABEL DRUG USE; RADIATION ABSORPTION; RADIOISOTOPE THERAPY; UNSPECIFIED SIDE EFFECT; VEIN THROMBOSIS;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; THIAZOLIDINEDIONES; THYROID NEOPLASMS; THYROIDECTOMY; TREATMENT OUTCOME; WHOLE BODY IMAGING;

EID: 84857230434     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e3182443ca6     Document Type: Article

References (23)

1. Goretzki PE, Simon D, Frilling A, et al. Surgical reintervention for differentiated thyroid carcinoma. Br J Surg. 1994;80:1131-1134.
2. Frey P, Townsend D, Flattet A, et al. Tomographic imaging of the human thyroid using I-124. J. Clin. Endocrinol. Metab. 1986;63:918-927. (Pubitemid 16004296)
3. Riemann B, Krämer JA, Schmid KW, et al. Risikostratifizierung von Patienten mit lokal aggressiven differenzierten Schilddrüsenkrebs- Ergebnisse der MSDS-Studie; results of the MSDS trial. Nuklearmedizin. 2010;49:79-123.
4. Filetti S, Bidart JM, Arturi F, et al. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol. 1999;141:443-457.
5. Grüning T, Tiepolt C, Zöphel K, et al. Retinoic acid for redifferentiation of thyroid cancer-does it hold its promise? Eur J Endocrinol. 2003;148:395-402. (Pubitemid 36527410)
6. Simon D, Korber C, Krausch M, et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. EJNM. 2002;29:775-782.
7. Haugen BR. Redifferentiation therapy in advanced thyroid cancer. Curr Drug Targets Immune Endocr Metabol Disord. 2004;4:175-180. (Pubitemid 39199355)
8. Spitzweg C, Harrington KJ, Pinke LA, et al. Clinical review 132: the sodium iodide symporter and its potential role in cancer therapy. J Clin Endocrinol Metab. 2001;86:3327-3335. (Pubitemid 32673505)
9. Fröhlich E, Brossart P, Wahl R. Effects of retinoids on porcine thyrocytes under different culture conditions. Histochemical Journal. 2001;33:295-304. (Pubitemid 32807979)
10. Fröhlich E, Machicao F, Wahl R. Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture. ERC. 2005;12:291-303. (Pubitemid 40896448)
11. Koeffler HP. Peroxisome proliferator-activated receptor gamma and cancers. Clin Cancer Res. 2003;9:1-9. (Pubitemid 36109710)
12. Panigrahy D, Singer S, Shen LQ, et al. PPAR-gamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest. 2002;110:923-932.
13. Park JW, Zarnegar R, Kanauchi H, et al. Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. Thyroid. 2005;15:222-231. (Pubitemid 40418689)
14. Jentzen W, Freudenberg L, Eising EG, et al. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer. J Nucl Med. 2008;49:1017-1023. (Pubitemid 351793444)
15. Kebebew E, Peng M, Reiff E, et al. A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer. Surgery. 2006;140:960-967. (Pubitemid 44937397)
16. Martelli ML, Iuliano R, Le Pera I, et al. Inhibitory effects of peroxisome proliferator-activated receptor gamma on thyroid carcinoma cell growth. J Clin Endocrinol Metab. 2002;87:4728-4735. (Pubitemid 35247068)
17. Rumi MA, Ishihara S, Kazumori H, et al. Can PPAR gamma ligands be used in cancer therapy? Curr Med Chem Anticancer Agents. 2004;4:465-477. (Pubitemid 39406260)
18. Padhani AR, Ollivier L. The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diagnostic radiologists. Br J Radiol. 2001; 74:983-986. (Pubitemid 33121128)
19. Antoch G, Jentzen W, Freudenberg LS, et al. Effect of oral contrast agents on computed tomography-based positron emission tomography attenuation correction in dual-modality positron emission tomography/computed tomography imaging. Invest Radiol. 2003;38:784-789. (Pubitemid 37444951)
20. Jentzen W, Freudenberg L, Eising EG, et al. Segmentation of PET volumes by iterative image thresholding. J Nucl Med. 2007;48:1008-1014.
21. Kebebew E, Lindsay S, Clark OH, et al. Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer. Thyroid. 2009;19:953-956.
22. Tepmongkol S, Keelawat S, Honsawek S, et al. Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: a correlation with the expression of peroxisome proliferator-activated receptor-gamma. Thyroid. 2008;18:697-704. (Pubitemid 352009939)
23. Görges R. Schilddrüsenkarzinome mit Follikelzellursprung. In: Schott M, ed. Moderne Labordiagnostik von Schilddrüsenerkrankungen: Bremen, Uni-ScienceMed, SD-Labordiagnostik. In press.